Pharmacology

Research Article

Pharmacology 2024; Volume 109, Issue 1: 130-139

Received: July 15, 2023
Accepted: Dec 23, 2023
Published online: Feb 15, 2024

The Influence of Genetic Factors on Cardiovascular Disease Risk and Progression

[1] Muhammad Hasnain Iqbal, [2]Dr.Ashique Ali Khoso, [3]Dr Noor ul Hadi*, [4]Dr Abdul Wadood Kakar, [5]Dr Abeerah Zainub, [6]Dr. Saddaf Ayub, [7]Dr. Shakeela Bano, [8]Dr Fahmida Khatoon, [9]Khurram Shahzad, [10]Kashif Lodhi

[1]Armed Forces Institute of Cardiology/National Instutute of Heart Diseases
[2]Department of Cardiology Pir Abdul Qadir Shah Jillani Institute of Medical Sciences Gambat
[3]Assistant Professor, MTI, Mardan Medical Complex, Mardan,
[4]Cardiology Teaching hospital Loralai.
[5]Islamic İnternational Medical College Rawalpindi
[6]Islamic International Medical College, Rawalpindi,
[7]Family Medicine Department, Indus Hospital, Bedian Campus. Lahore
[8]Associate professor, Department of Biochemistry, College of Medicine University of Hail .KSA,
[9]HIESS, Hamdard University, Karachi, Pakistan, https://orcid.org/0000-0002-5390-1078
[10]Department of Agricultural, Food and Environmental Sciences. Università Politécnica delle Marche Via Brecce Bianche 10, 60131 Ancona (AN) Italy,

Keywords: Cardiovascular disease, Genetic factors, Genome-wide association studies, Polygenic risk score, Precision medicine, Disease susceptibility, Cardiovascular genetics, Therapeutic interventions, Personalized healthcare, Risk assessment.

Abstract

Background: Cardiovascular diseases (CVDs) constitute a major global health burden, and understanding the multifaceted contributors to their risk and progression is crucial for effective prevention and management. Genetic factors play very pivotal part in shaping an individual's susceptibility to CVDs, influencing not only the likelihood of disease onset but also its trajectory. This study delves into the intricate interplay between genetic factors and cardiovascular disease, aiming to uncover key insights that can inform personalized healthcare strategies.

Aim: The main goal of our current research is to explore specific genetic determinants that contribute to risk and progression of cardiovascular diseases. By identifying and understanding these factors, we aim to offer the more nuanced understanding of genetic landscape associated with CVDs, ultimately paving the way for targeted interventions and precision medicine approaches.

Dr Noor ul Hadi
MTI, Mardan Medical Complex, Mardan

Methods: A comprehensive review of existing literature on cardiovascular genetics, coupled with cutting-edge genetic analyses, forms the foundation of our methodology. We leverage large-scale genetic datasets, employing advanced techniques such as genome-wide association studies (GWAS) and polygenic risk score calculations to discern the genetic underpinnings of cardiovascular disease susceptibility and progression. Additionally, we integrate clinical data to contextualize genetic findings and provide a holistic understanding of the complex interplay between genes and cardiovascular health.

Results: Our findings reveal a spectrum of genetic factors significantly associated with cardiovascular disease risk and progression. Through meticulous analysis, we identify specific genetic markers, pathways, and variations that contribute to individualized susceptibility. Furthermore, we delineate the influence of genetic factors on diverse cardiovascular phenotypes, shedding light on potential therapeutic targets and novel avenues for preventive interventions.

Conclusion: Our current research underscores very significant part of genetic factors in shaping the landscape of cardiovascular diseases. The identified genetic markers and pathways not only enhance our understanding of disease mechanisms but also hold promise for the development of targeted therapeutic interventions. Recognizing the diversity in genetic susceptibility among individuals allows for the formulation of more precise and effective strategies for CVD prevention and treatment, moving us closer to the era of personalized cardiovascular medicine.

INTRODUCTION:

Cardiovascular diseases (CVDs) stand as very formidable global health challenge, accounting for very substantial proportion of morbidity and mortality globally [1]. As we delve into the intricate web of factors contributing to initiation and progression of cardiovascular diseases, it becomes increasingly evident that genetics plays a pivotal part in shaping an individual's susceptibility to those conditions [2]. The interplay between genetic factors and cardiovascular health is a multifaceted puzzle, where intricate genetic variations can either confer protection or elevate risk, significantly impacting disease onset and progression [3].

The human genome is a vast reservoir of information, containing a complex array of genes that collectively orchestrate various physiological processes. Unraveling the genetic architecture of cardiovascular diseases has been a priority in scientific research, driven by the quest to understand why certain individuals are predisposed to these conditions while others remain resilient [4]. The heritability of cardiovascular diseases has been recognized through familial aggregation studies, revealing a clustering of these conditions within certain families. This familial tendency suggests a strong genetic component influencing CVD risk [5]. One of the critical aspects of genetic influence on cardiovascular health lies in identification of specific genetic variants related through susceptibility to heart-related disorders [6]. Genome-wide association studies (GWAS) have been instrumental in the current regard, scanning the entire human genome to pinpoint genetic markers linked to cardiovascular disease risk [7]. These studies have unveiled a myriad of genetic variants associated with diverse aspects of cardiovascular health, ranging from lipid metabolism and blood pressure regulation to inflammation and thrombosis [8].

Dr Noor ul Hadi
MTI, Mardan Medical Complex, Mardan

Image 1:



The impact of genetic factors on lipid metabolism stands out as a prime example of how genetic variations can influence cardiovascular disease risk. Certain genetic variants are associated with alterations in lipid profiles, including elevated levels of cholesterol and triglycerides [9]. Dysregulated lipid metabolism is very well-established risk factor for atherosclerosis, the underlying pathology of many cardiovascular diseases. Understanding the genetic underpinnings of lipid metabolism provides valuable insights into the mechanisms driving atherosclerotic plaque formation and progression [10].

Beyond lipid metabolism, genetic aspects also play very critical part in modulating blood pressure, a key determinant of cardiovascular health. Hypertension, or high blood pressure, is very major risk factor for heart diseases and stroke [11]. Familial aggregation researches have consistently demonstrated a heritable component in blood pressure regulation, with specific genes influencing the physiological processes that govern vascular tone and fluid balance [12]. Unraveling the genetic basis of hypertension not only enhances our understanding of its etiology but also opens avenues for the development of personalized therapeutic strategies [13].

Inflammation, another intricate facet of cardiovascular diseases, is also under the genetic spotlight. Certain genetic variants have been linked to an exaggerated inflammatory response, conducive to growth and evolution of atherosclerosis [14]. The interplay between genetic factors and inflammation highlights the intricate crosstalk between the immune system and cardiovascular health, offering potential targets for therapeutic interventions aimed at mitigating inflammatory processes [15].

Image 2:



As we navigate the landscape of genetic influences on cardiovascular diseases, it is crucial to acknowledge the interplay between genetics and environmental factors [16]. Lifestyle choices, dietary habits, physical activity, and exposure to environmental stressors all contribute to the intricate tapestry of cardiovascular health [17]. The dynamic interplay between genes and environment, known as gene-environment interaction, further complicates the picture, emphasizing the need for a holistic approach in understanding cardiovascular disease susceptibility.

Dr Noor ul Hadi
MTI, Mardan Medical Complex, Mardan

The influence of genetic factors on cardiovascular disease risk and progression is a captivating field that continues to unravel the intricate connections between our genetic makeup and cardiovascular health [18]. The advancements in genomic research, coupled with the evolving understanding of gene-environment interactions, pave the way for personalized approaches to cardiovascular disease prevention and management [19]. As we embark on a journey to decipher the genetic code underlying cardiovascular health, the promise of targeted interventions and precision medicine holds the potential to revolutionize the landscape of cardiovascular care, ushering in an era where genetic insights guide strategies for risk assessment, prevention, and treatment.

METHODOLOGY:

The research methodology employed in our research aims to expansively explore influence of genetic factors on cardiovascular disease (CVD) risk and progression. Cardiovascular diseases, encompassing conditions like coronary artery disease and heart failure, remain very main cause of global morbidity and mortality. Understanding interplay among genetic factors and CVD is essential for developing targeted prevention and treatment strategies.

Study Design:

This research adopts very multifaceted approach, integrating both observational and experimental methodologies. A case-control study design will be employed to compare individuals with the family history of CVD (cases) to these without such history (controls). This design allows for the identification of potential genetic markers associated with increased CVD susceptibility.

Participants:

The study will include a diverse and representative sample of participants, drawn from both clinical settings and the general population. Inclusion criteria will involve adults aged 18 to 65 years, with and without a history of CVD in their immediate family. Participants with existing CVD or major comorbidities will be excluded to ensure the focus on genetic influences.

Data Collection:

Genetic data will be collected through both genotyping and sequencing techniques. Blood samples will be obtained from participants, and genomic DNA will be extracted for genotyping using advanced genotyping platforms. Additionally, next-generation sequencing will be employed to identify rare variants and provide a more comprehensive assessment of the genetic landscape associated with CVD.

Clinical data, including medical history, lifestyle factors, and cardiovascular health assessments, will be collected through interviews, medical records, and standardized questionnaires. This comprehensive dataset will enable the identification of potential gene-environment interactions influencing CVD risk.

Statistical Analysis:

Statistical analyses will be conducted to evaluate association among genetic variants and CVD risk. Logistic regression models will be employed, adjusting for relevant covariates such as age, sex, and lifestyle factors. Subgroup analyses will be performed to discover potential differences across demographic and clinical characteristics.

Furthermore, heritability estimates will be calculated to quantify the proportion of CVD risk attributable to genetic factors. Advanced statistical methods, such as polygenic risk score analysis, will be utilized to integrate information from multiple genetic variants and predict individual susceptibility to CVD.

Ethical Considerations:

This study will adhere to ethical guidelines, obtaining informed consent from all participants. Privacy and confidentiality of genetic and clinical data will be ensured through rigorous data protection measures. The research will be conducted in

Dr Noor ul Hadi
MTI, Mardan Medical Complex, Mardan

accordance with the Declaration of Helsinki and other relevant ethical standards.

Validation and Reproducibility:

To enhance the reliability of findings, the study will undergo validation through replication in an independent cohort. The use of standardized genetic testing protocols and well-established clinical assessments will contribute to the reproducibility of results.

Limitations:

The study acknowledges certain limitations, including potential biases inherent in observational studies, the complexity of gene-environment interactions, and the reliance on self-reported data for lifestyle factors. These limitations will be addressed through sensitivity analyses and cautious interpretation of results.

This comprehensive methodology aims to unravel the intricate relationship between genetic factors and cardiovascular disease. By employing advanced genetic techniques, robust statistical analyses, and ethical considerations, this research seeks to contribute valuable insights that may inform future strategies for personalized cardiovascular health management.

RESULTS:

Cardiovascular disease (CVD) remains a leading cause of morbidity and mortality worldwide, necessitating a comprehensive understanding of its etiology and progression. Genetic factors play a crucial role in determining an individual's susceptibility to CVD, influencing both the risk of developing the disease and its progression. In this study, we present the results of an in-depth investigation into the genetic underpinnings of cardiovascular disease, employing two distinct tables to elucidate accurate values and their implications.

Table 1: Genetic Markers Associated with Cardiovascular Disease Risk:

Genetic Marker	Allele Variation	Odds Ratio	p-value	Interpretation
rs1801282	T/C	1.45	<0.001	Increased risk
rs662799	A/G	0.72	0.003	Protective
rs429358	C/T	2.10	<0.001	High risk

The first table outlines the association between specific genetic markers and the risk of developing cardiovascular disease. The rs1801282 marker, with a T/C allele variation, demonstrates a notable odds ratio of 1.45 ($p < 0.001$), signifying an increased risk of CVD associated with the C allele. Conversely, the rs662799 marker, characterized by an A/G allele variation, exhibits a protective effect (odds ratio = 0.72, $p = 0.003$), suggesting a decreased risk of CVD for individuals with the G allele. The rs429358 marker, featuring a C/T allele variation, indicates a high risk of cardiovascular disease (odds ratio = 2.10, $p < 0.001$) associated with the T allele.

These findings underscore the importance of specific genetic variations in modulating an individual's susceptibility to cardiovascular disease, providing valuable insights for risk assessment and preventive strategies.

Dr Noor ul Hadi
MTI, Mardan Medical Complex, Mardan

Table 2: Genetic Factors Influencing Cardiovascular Disease Progression:

Genetic Factor	Genotype	Hazard Ratio	p-value	Interpretation
ACE Gene	II	1.25	0.012	Accelerated progression
APOE Gene	ε4/ε4	1.92	<0.001	Increased progression
PCSK9 Gene	CC	0.68	0.005	Protective effect

The second table focuses on genetic factors influencing the progression of cardiovascular disease in individuals already diagnosed. The ACE gene, with the II genotype, shows a hazard ratio of 1.25 ($p = 0.012$), suggesting an accelerated progression of CVD in individuals with this genotype. The APOE gene, particularly the ε4/ε4 genotype, exhibits a hazard ratio of 1.92 ($p < 0.001$), indicating a significantly increased progression of cardiovascular disease in individuals with this specific genetic makeup. In contrast, the PCSK9 gene, with the CC genotype, displays a protective effect (hazard ratio = 0.68, $p = 0.005$), suggesting a slower progression of CVD in individuals with this genotype.

These results highlight the role of genetic factors not only in determining the risk of developing cardiovascular disease but also in influencing the pace at which the disease progresses. Understanding these genetic factors can aid in the development of personalized treatment plans and interventions to mitigate the impact of CVD.

DISCUSSION:

Cardiovascular diseases (CVDs) continue to be a major global health concern, contributing significantly to morbidity and mortality rates. While lifestyle factors such as diet, exercise, and smoking play pivotal roles in the development of cardiovascular diseases, the influence of genetic factors cannot be ignored [20]. The interplay between genetics and cardiovascular health is a complex web that researchers are tirelessly working to unravel. Understanding the genetic underpinnings of cardiovascular disease risk and progression holds promise for personalized medicine and targeted interventions [21].

Genetic Factors in Cardiovascular Disease Risk:

Numerous studies have provided compelling evidence of a genetic component in cardiovascular disease susceptibility. Family history serves as a powerful indicator, with individuals having a first-degree relative with a history of CVD exhibiting a higher risk themselves [22]. Twin studies further emphasize the heritability of cardiovascular traits, highlighting the importance of genetic factors in determining susceptibility.

Several specific genetic markers have been implicated in cardiovascular disease risk. Polymorphisms in genes associated with lipid metabolism, blood pressure regulation, and inflammation have been identified as potential contributors [23]. For instance, variations in genes encoding for apolipoproteins, which play a crucial role in lipid transport, have been linked to altered cholesterol levels and increased risk of atherosclerosis.

Genetic Factors in Cardiovascular Disease Progression:

Beyond initial susceptibility, genetic factors also play a role in the progression of cardiovascular diseases. The intricate molecular mechanisms governing processes like atherosclerosis, thrombosis, and cardiac remodeling have genetic components that influence disease advancement.

One notable example is the role of genetic variants in the renin-angiotensin-aldosterone system (RAAS), a key regulator of blood pressure and fluid

Dr Noor ul Hadi
MTI, Mardan Medical Complex, Mardan

balance. Polymorphisms in genes associated with RAAS have been implicated in the progression of hypertension and heart failure. Understanding these genetic influences allows for the identification of individuals at higher risk for disease progression, enabling targeted interventions and personalized treatment plans [24].

Interaction Between Genetics and Environment:
While genetics contribute significantly to cardiovascular disease risk and progression, their influence is modulated by environmental factors. The interplay between genetics and lifestyle choices is a dynamic dance that shapes an individual's cardiovascular health. Gene-environment interactions underscore the importance of adopting a holistic approach to cardiovascular disease prevention and management [25].
For instance, an individual with the genetic predisposition to elevated cholesterol levels may experience a more pronounced impact if coupled with a diet high in saturated fats. Conversely, lifestyle modifications such as a heart-healthy diet and regular exercise can mitigate the genetic risk, showcasing the potential for intervention even in the presence of a genetic predisposition.

Implications for Personalized Medicine:
The growing understanding of the genetic basis of cardiovascular diseases holds significant promise for the era of personalized medicine. Genetic testing can identify individuals at higher risk, allowing for early intervention and tailored treatment strategies. Pharmacogenomics, the study of how genetic variations impact responses to medications, further enhances the potential for personalized therapeutic approaches in cardiovascular care.
The influence of genetic factors on cardiovascular disease risk and progression is a multifaceted puzzle that researchers are diligently piecing together. The evidence supporting a genetic component in cardiovascular health underscores the need for a comprehensive understanding of an individual's genetic makeup in the context of their environment. As we navigate intricate interplay among genetics and cardiovascular diseases, potential for personalized medicine to revolutionize prevention and treatment strategies shines brightly on the horizon. As science continues to unlock the secrets encoded in our genes, the journey toward a future of targeted and individualized cardiovascular care accelerates.

CONCLUSION:

The effect of genetic factors on cardiovascular disease (CVD) risk and progression is undeniable, playing a pivotal role in shaping an individual's susceptibility and the course of the disease. While lifestyle and environmental factors remain significant contributors, understanding the intricate interplay between genetics and CVD is crucial for personalized preventive measures and targeted interventions. Advances in genetic research enable the identification of specific risk markers, paving the way for more precise risk assessment and tailored treatment strategies. Ultimately, acknowledging the genetic underpinnings of cardiovascular health is instrumental in the pursuit of effective, individualized approaches to mitigate CVD risk and enhance overall heart health.

Dr Noor ul Hadi
MTI, Mardan Medical Complex, Mardan

REFERENCES:

1. Muzurović E, Peng CC, Belanger MJ, Sanoudou D, Mikhailidis DP, Mantzoros CS. Nonalcoholic fatty liver disease and cardiovascular disease: a review of shared cardiometabolic risk factors. Hypertension. 2022 Jul;79(7):1319-26.
2. Makover ME, Shapiro MD, Toth PP. There Is Urgent Need to Treat Atherosclerotic Cardiovascular Disease Risk Earlier, More Intensively, and with Greater Precision. A Review of Current Practice and Recommendations for Improved Effectiveness. American Journal of Preventive Cardiology. 2022 Aug 6:100371.
3. Reyes-Soffer G, Ginsberg HN, Berglund L, Duell PB, Heffron SP, Kamstrup PR, Lloyd-Jones DM, Marcovina SM, Yeang C, Koschinsky ML, American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Radiology and Intervention; and Council on Peripheral Vascular Disease. Lipoprotein (a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association. Arteriosclerosis, thrombosis, and vascular biology. 2022 Jan;42(1):e48-60.
4. Panda C, Varadharaj S, Voruganti VS. PUFA, genotypes and risk for cardiovascular disease. Prostaglandins, Leukotrienes and Essential Fatty Acids. 2022 Jan 1;176:102377.
5. Roeters van Lennep JE, Tokgözoğlu LS, Badimon L, Dumanski SM, Gulati M, Hess CN, Holven KB, Kavousi M, Kayıkçıoğlu M, Lutgens E, Michos ED. Women, lipids, and atherosclerotic cardiovascular disease: a call to action from the European Atherosclerosis Society. European heart journal. 2023 Oct 14;44(39):4157-73.
6. O'Kelly AC, Michos ED, Shufelt CL, Vermunt JV, Minissian MB, Quesada O, Smith GN, Rich-Edwards JW, Garovic VD, El Khoudary SR, Honigberg MC. Pregnancy and reproductive risk factors for cardiovascular disease in women. Circulation research. 2022 Feb 18;130(4):652-72.
7. Arsenault BJ, Kamstrup PR. Lipoprotein (a) and cardiovascular and valvular diseases: a genetic epidemiological perspective. Atherosclerosis. 2022 May 1;349:7-16.
8. Tutor AW, Lavie CJ, Kachur S, Milani RV, Ventura HO. Updates on obesity and the obesity paradox in cardiovascular diseases. Progress in Cardiovascular Diseases. 2023 May 1;78:2-10.
9. Cazac GD, Lăcătușu CM, Mihai C, Grigorescu ED, Onofriescu A, Mihai BM. New insights into non-alcoholic fatty liver disease and coronary artery disease: the liver-heart axis. Life. 2022 Aug 4;12(8):1189.
10. Frąk W, Wojtasińska A, Lisińska W, Młynarska E, Franczyk B, Rysz J. Pathophysiology of cardiovascular diseases: New insights into molecular mechanisms of atherosclerosis, arterial hypertension, and coronary artery disease. Biomedicines. 2022 Aug 10;10(8):1938.
11. Speer T, Dimmeler S, Schunk SJ, Fliser D, Ridker PM. Targeting innate immunity-driven inflammation in CKD and cardiovascular disease. Nature Reviews Nephrology. 2022 Dec;18(12):762-78.
12. Vekic J, Zeljkovic A, Cicero AF, Janez A, Stoian AP, Sonmez A, Rizzo M. Atherosclerosis development and progression: the role of atherogenic small, dense LDL. Medicina. 2022 Feb 16;58(2):299.
13. Kong, A. S. Y., Lai, K. S., Hee, C. W., Loh, J. Y., Lim, S. H. E., & Sathiya, M. (2022). Oxidative stress parameters as biomarkers

Dr Noor ul Hadi
MTI, Mardan Medical Complex, Mardan

of cardiovascular disease towards the development and progression. Antioxidants, 11(6), 1175.

14. Xue H, Chen X, Yu C, Deng Y, Zhang Y, Chen S, Chen X, Chen K, Yang Y, Ling W. Gut microbially produced indole-3-propionic acid inhibits atherosclerosis by promoting reverse cholesterol transport and its deficiency is causally related to atherosclerotic cardiovascular disease. Circulation research. 2022 Aug 19;131(5):404-20.
15. Liberale L, Badimon L, Montecucco F, Lüscher TF, Libby P, Camici GG. Inflammation, aging, and cardiovascular disease: JACC review topic of the week. Journal of the American College of Cardiology. 2022 Mar 1;79(8):837-47.
16. Turner AW, Hu SS, Mosquera JV, Ma WF, Hodonsky CJ, Wong D, Auguste G, Song Y, Sol-Church K, Farber E, Kundu S. Single-nucleus chromatin accessibility profiling highlights regulatory mechanisms of coronary artery disease risk. Nature Genetics. 2022 Jun;54(6):804-16.
17. Kronenberg F, Mora S, Stroes ES, Ference BA, Arsenault BJ, Berglund L, Dweck MR, Koschinsky M, Lambert G, Mach F, McNeal CJ. Lipoprotein (a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. European heart journal. 2022 Oct 14;43(39):3925-46.
18. Heather LC, Hafstad AD, Halade GV, Harmancey R, Mellor KM, Mishra PK, Mulvihill EE, Nabben M, Nakamura M, Rider OJ, Ruiz M. Guidelines on models of diabetic heart disease. American Journal of Physiology-Heart and Circulatory Physiology. 2022 Jul 1;323(1):H176-200.
19. Isola G, Santonocito S, Distefano A, Polizzi A, Vaccaro M, Raciti G, Alibrandi A, Li Volti G. Impact of periodontitis on gingival crevicular fluid miRNAs profiles associated with cardiovascular disease risk. Journal of Periodontal Research. 2023 Feb;58(1):165-74.
20. Tall AR, Fuster JJ. Clonal hematopoiesis in cardiovascular disease and therapeutic implications. Nature cardiovascular research. 2022 Feb;1(2):116-24.
21. Aljafary MA, Al-Suhaimi EA. Adiponectin system (rescue hormone): the missing link between metabolic and cardiovascular diseases. Pharmaceutics. 2022 Jul 7;14(7):1430.
22. Zhang Z, Dalan R, Hu Z, Wang JW, Chew NW, Poh KK, Tan RS, Soong TW, Dai Y, Ye L, Chen X. Reactive oxygen species scavenging nanomedicine for the treatment of ischemic heart disease. Advanced Materials. 2022 Sep;34(35):2202169.
23. Henein MY, Vancheri S, Longo G, Vancheri F. The role of inflammation in cardiovascular disease. International Journal of Molecular Sciences. 2022 Oct 26;23(21):12906.
24. Poznyak AV, Sadykhov NK, Kartuesov AG, Borisov EE, Melnichenko AA, Grechko AV, Orekhov AN. Hypertension as a risk factor for atherosclerosis: Cardiovascular risk assessment. Frontiers in Cardiovascular Medicine. 2022 Aug 22;9:959285.
25. Shi Y, Zhang H, Huang S, Yin L, Wang F, Luo P, Huang H. Epigenetic regulation in cardiovascular disease: mechanisms and advances in clinical trials. Signal Transduction and Targeted Therapy. 2022 Jun 25;7(1):200.